JP6925969B2 - 医薬組成物 - Google Patents

医薬組成物 Download PDF

Info

Publication number
JP6925969B2
JP6925969B2 JP2017541780A JP2017541780A JP6925969B2 JP 6925969 B2 JP6925969 B2 JP 6925969B2 JP 2017541780 A JP2017541780 A JP 2017541780A JP 2017541780 A JP2017541780 A JP 2017541780A JP 6925969 B2 JP6925969 B2 JP 6925969B2
Authority
JP
Japan
Prior art keywords
pth
composition
snac
protease inhibitor
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017541780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018504444A5 (ja
JP2018504444A (ja
Inventor
グレゴリー バーシュテイン
グレゴリー バーシュテイン
アリエル ロスナー
アリエル ロスナー
フィリップ エム シュワルツ
フィリップ エム シュワルツ
ヒレル ガリッツァー
ヒレル ガリッツァー
Original Assignee
エンテラ バイオ エルティーディー．
エンテラ バイオ エルティーディー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンテラ バイオ エルティーディー．, エンテラ バイオ エルティーディー． filed Critical エンテラ バイオ エルティーディー．
Publication of JP2018504444A publication Critical patent/JP2018504444A/ja
Publication of JP2018504444A5 publication Critical patent/JP2018504444A5/ja
Priority to JP2021128281A priority Critical patent/JP7275207B2/ja
Application granted granted Critical
Publication of JP6925969B2 publication Critical patent/JP6925969B2/ja
Priority to JP2023015960A priority patent/JP7775239B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
JP2017541780A 2015-02-09 2016-02-09 医薬組成物 Active JP6925969B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021128281A JP7275207B2 (ja) 2015-02-09 2021-08-04 骨粗鬆症の治療
JP2023015960A JP7775239B2 (ja) 2015-02-09 2023-02-06 骨粗鬆症の治療

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201562113600P 2015-02-09 2015-02-09
US201562113638P 2015-02-09 2015-02-09
US201562113625P 2015-02-09 2015-02-09
US201562113619P 2015-02-09 2015-02-09
US201562113604P 2015-02-09 2015-02-09
US201562113673P 2015-02-09 2015-02-09
US201562113629P 2015-02-09 2015-02-09
US62/113,604 2015-02-09
US62/113,638 2015-02-09
US62/113,629 2015-02-09
US62/113,600 2015-02-09
US62/113,673 2015-02-09
US62/113,625 2015-02-09
US62/113,619 2015-02-09
PCT/IL2016/050154 WO2016128973A1 (en) 2015-02-09 2016-02-09 Treatment of osteoporosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021128281A Division JP7275207B2 (ja) 2015-02-09 2021-08-04 骨粗鬆症の治療

Publications (3)

Publication Number Publication Date
JP2018504444A JP2018504444A (ja) 2018-02-15
JP2018504444A5 JP2018504444A5 (ja) 2019-03-14
JP6925969B2 true JP6925969B2 (ja) 2021-08-25

Family

ID=56614456

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2017541780A Active JP6925969B2 (ja) 2015-02-09 2016-02-09 医薬組成物
JP2017541786A Active JP6925970B2 (ja) 2015-02-09 2016-02-09 副甲状腺機能低下症の治療
JP2021128296A Pending JP2021176914A (ja) 2015-02-09 2021-08-04 副甲状腺機能低下症の治療
JP2021128281A Active JP7275207B2 (ja) 2015-02-09 2021-08-04 骨粗鬆症の治療
JP2023015960A Active JP7775239B2 (ja) 2015-02-09 2023-02-06 骨粗鬆症の治療
JP2023078011A Pending JP2023100920A (ja) 2015-02-09 2023-05-10 副甲状腺機能低下症の治療

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017541786A Active JP6925970B2 (ja) 2015-02-09 2016-02-09 副甲状腺機能低下症の治療
JP2021128296A Pending JP2021176914A (ja) 2015-02-09 2021-08-04 副甲状腺機能低下症の治療
JP2021128281A Active JP7275207B2 (ja) 2015-02-09 2021-08-04 骨粗鬆症の治療
JP2023015960A Active JP7775239B2 (ja) 2015-02-09 2023-02-06 骨粗鬆症の治療
JP2023078011A Pending JP2023100920A (ja) 2015-02-09 2023-05-10 副甲状腺機能低下症の治療

Country Status (9)

Country Link
US (8) US10583177B2 (enExample)
EP (5) EP3256114A4 (enExample)
JP (6) JP6925969B2 (enExample)
CN (5) CN114949185A (enExample)
CA (3) CA2975710C (enExample)
HK (5) HK1247823A1 (enExample)
IL (7) IL292417B2 (enExample)
MX (2) MX2017010220A (enExample)
WO (5) WO2016128974A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE036066T2 (hu) 2010-12-16 2018-06-28 Novo Nordisk As GLP-1 agonistát és N-(8-(2-hidroxibenzoil)amino)kaprilsav sóját tartalmazó szilárd készítmények
EP3225631B1 (en) 2011-04-12 2019-01-09 Novo Nordisk A/S Double-acylated glp-1 derivatives
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
HRP20181447T1 (hr) 2012-03-22 2018-11-02 Novo Nordisk A/S Pripravci glp-1 peptida i njihova priprava
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
MY172578A (en) 2013-05-02 2019-12-03 Novo Nordisk As Oral dosing of glp-1 compounds
CN114949185A (zh) 2015-02-09 2022-08-30 安特拉贝欧有限公司 骨质疏松症的治疗
JP7530173B2 (ja) * 2016-08-17 2024-08-07 エンテラ バイオ エルティーディー． 活性薬剤の経口投与のための製剤
RS64643B1 (sr) 2018-02-02 2023-10-31 Novo Nordisk As Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline i lubrikant
KR20210137373A (ko) * 2019-03-08 2021-11-17 안야 바이오팜 인코포레이티드 부갑상샘 호르몬 유사체의 경구 제제 및 치료
MX2022002612A (es) * 2019-09-03 2022-05-06 Amgen Inc Composiciones de il-22 orales, intrarrectales u otras relacionadas con el intestino y metodos de uso de las mismas.
CN114306249A (zh) * 2020-09-28 2022-04-12 深圳翰宇药业股份有限公司 一种特立帕肽冻干药物组合物及其制备方法
US12251208B2 (en) * 2020-11-30 2025-03-18 International Business Machines Corporation Time controlled medication
CN114288388B (zh) * 2022-01-25 2023-11-03 华中科技大学同济医学院附属协和医院 网膜素在制备炎症性肠病治疗药物中的应用
EP4482515A4 (en) * 2022-02-24 2025-12-31 Entera Bio Ltd FORMULATIONS COMPRISING AN ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE
WO2023161938A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of kappa opioid receptor agonist peptide
WO2023161935A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of growth hormone
WO2023161936A1 (en) * 2022-02-24 2023-08-31 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of growth hormone-releasing hormone
IL315198A (en) * 2022-02-24 2024-10-01 Entera Bio Ltd Formulations comprising acid-neutralizing polymer for oral administration of active agents
US20250186555A1 (en) * 2022-02-24 2025-06-12 Entera Bio Ltd. Formulations comprising acid-neutralizing polymer for oral administration of glucagon-like peptide-2
KR20240150507A (ko) * 2022-02-24 2024-10-15 엔테라 바이오 리미티드 글루카곤 유사 펩타이드-1 및 이의 유사체의 경구 투여를 위한 산 중화 중합체를 포함하는 제형
WO2025046590A1 (en) * 2023-08-30 2025-03-06 Entera Bio Ltd. Formulations for oral administration of active agents
WO2025046589A1 (en) * 2023-08-30 2025-03-06 Entera Bio Ltd. Formulations comprising a combination of acid-neutralizing polymeric and non-polymeric substances for oral administration of active agents
WO2025146144A1 (zh) * 2024-01-05 2025-07-10 成都国为生物医药有限公司 一种地非法林的口服药物组合物
WO2025240494A1 (en) 2024-05-13 2025-11-20 Lumen Bioscience, Inc. Leptin compositions and methods of making and using the same to support weight loss and/or maintenance

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5360793A (en) * 1993-05-24 1994-11-01 Sterling Winthrop Inc. Rafting antacid formulation
CN1162917A (zh) * 1994-10-07 1997-10-22 伯温德药品服务公司 肠内涂层组合物，用其涂覆的方法和涂覆制品
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
CA2220301C (en) * 1995-06-02 2006-02-21 Alza Corporation Osmotic device with delayed activation of drug delivery and complete drug release
JP3880093B2 (ja) 1995-08-08 2007-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 錠剤
JP3220373B2 (ja) 1995-11-28 2001-10-22 バイエル薬品株式会社 持続性ニフエジピン製剤
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
EP0943336A1 (en) 1996-09-04 1999-09-22 Dott Research Laboratory Peptide-containing pharmaceutical compositions for oral administration
EP0986395A4 (en) 1997-05-14 2004-12-01 Aventis Pharm Prod Inc PEPTIDE ANALOGS OF THE PARATHYROID HORMONE
US6531152B1 (en) 1998-09-30 2003-03-11 Dexcel Pharma Technologies Ltd. Immediate release gastrointestinal drug delivery system
AU3240900A (en) * 1999-02-22 2000-09-04 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
WO2000050386A1 (en) 1999-02-26 2000-08-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ATE288415T1 (de) 1999-04-05 2005-02-15 Emisphere Tech Inc Dinatrium-salze, monohydrate und ethanol-solvate
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
MXPA02004092A (es) 1999-11-05 2003-02-12 Emisphere Tech Inc Compuestos y composiciones de acido fenilaminocarboxilico para administrar agentes activos.
CA2395993A1 (en) * 1999-12-28 2001-07-05 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
ATE443527T1 (de) * 2001-08-17 2009-10-15 Novartis Pharma Gmbh 5-cnac zur oralen verabreichung von parathormonfragmenten
US7297794B2 (en) 2001-11-13 2007-11-20 Emisphere Technologies, Inc. Phenoxy amine compounds and compositions for delivering active agents
JP5196701B2 (ja) 2001-11-29 2013-05-15 エミスフィアー テクノロジーズ インコーポレイテッド クロモリンナトリウムの経口投与用製剤
AU2002354497A1 (en) 2001-12-19 2003-06-30 Sanwa Kagaku Kenkyusho Co., Ltd Release control type formed product
US20030198666A1 (en) 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
PE20040724A1 (es) 2002-08-01 2004-12-06 Novartis Ag Composicion para la administracion oral de calcitonina
WO2005002549A1 (en) 2003-07-04 2005-01-13 Nycomed Danmark Aps Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
JP2005281231A (ja) 2004-03-30 2005-10-13 Bioserentack Co Ltd 小腸ターゲットタイプの経口ｄｄｓ製剤
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
US20060078623A1 (en) * 2004-08-13 2006-04-13 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
JP2006111558A (ja) 2004-10-14 2006-04-27 Bioserentack Co Ltd 多層構造を有する錠剤状の小腸粘膜付着性経口製剤
MX2007005991A (es) 2004-11-19 2007-07-20 Smithkline Beecham Corp Producto farmaceutico.
WO2006076692A1 (en) * 2005-01-12 2006-07-20 Emisphere Technologies, Inc. Compositions for buccal delivery of parathyroid hormone
WO2006084164A2 (en) * 2005-02-01 2006-08-10 Emisphere Technologies, Inc. Gastric retention and controlled release delivery system
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
JP5123471B2 (ja) 2005-08-18 2013-01-23 帝人ファーマ株式会社 用量調整が容易な製剤
JP5222727B2 (ja) 2005-09-06 2013-06-26 オーラメッド・ファーマスーティカルズ・インコーポレイテッド タンパク質を経口投与するための方法及び組成物
WO2007061829A2 (en) 2005-11-17 2007-05-31 Novartis Ag Pharmaceutical composition
US20070178155A1 (en) * 2006-01-31 2007-08-02 Jiang David Yihai Preparation for gastric buoyant sustained drug release dosage form
US7704977B2 (en) 2006-04-07 2010-04-27 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
ES2538254T3 (es) 2006-04-18 2015-06-18 Emisphere Technologies, Inc. Agentes de administración de dialquil éter
KR101428826B1 (ko) * 2006-12-12 2014-08-08 가부시키가이샤 호리바 에스텍 유량 비율 제어 장치
WO2008122966A2 (en) 2007-04-04 2008-10-16 Sigmoid Pharma Limited A pharmaceutical composition of tacrolimus
WO2008132727A2 (en) * 2007-04-26 2008-11-06 Technion Research And Development Foundation Ltd Oral delivery of proteins and peptides
EP2200592A2 (en) * 2007-09-11 2010-06-30 Orahealth Corporation Adhering troches with topically active ingredients for treatment of throat, esophagus, and stomach
WO2009080764A2 (en) 2007-12-20 2009-07-02 Abylnx N.V. Oral or nasal administration of compounds comprising amino acid sequences
IT1393244B1 (it) * 2008-07-18 2012-04-12 Universita' Degli Studi Di Milano Sistema per il rilascio al colon di farmaci suscettibili di degradazione enzimatica e/o scarsamente assorbiti nel tratto gastrointestinale
CA2734442C (en) * 2008-08-18 2016-08-16 Oramed Ltd Methods and compositions for oral administration of proteins
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
MX2012012050A (es) * 2010-04-16 2012-11-22 Novartis Ag Metodos y composiciones para mejorar la oseointegracion de implantes.
HUE036066T2 (hu) * 2010-12-16 2018-06-28 Novo Nordisk As GLP-1 agonistát és N-(8-(2-hidroxibenzoil)amino)kaprilsav sóját tartalmazó szilárd készítmények
EP2747563A4 (en) 2011-08-26 2015-06-24 Aegis Therapeutics Llc COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF MEDICINAL PRODUCTS
WO2013067309A1 (en) * 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
CN114949185A (zh) 2015-02-09 2022-08-30 安特拉贝欧有限公司 骨质疏松症的治疗
JP7530173B2 (ja) * 2016-08-17 2024-08-07 エンテラ バイオ エルティーディー． 活性薬剤の経口投与のための製剤
JP7419862B2 (ja) 2020-02-14 2024-01-23 株式会社リコー 潤滑剤供給装置、プロセスカートリッジ、及び、画像形成装置

Also Published As

Publication number Publication date
IL292218B1 (en) 2024-06-01
US20180021272A1 (en) 2018-01-25
JP7775239B2 (ja) 2025-11-25
IL292417B2 (en) 2024-12-01
IL303216A (en) 2023-07-01
CN113730556A (zh) 2021-12-03
EP3256113B1 (en) 2025-04-02
IL283258B2 (en) 2023-11-01
MX2017010220A (es) 2018-02-21
CA2975578A1 (en) 2016-08-18
CN113694190A (zh) 2021-11-26
IL253804B (en) 2022-05-01
US20180028622A1 (en) 2018-02-01
IL292218A (en) 2022-06-01
JP2021176913A (ja) 2021-11-11
CN114949185A (zh) 2022-08-30
CN113694190B (zh) 2024-05-07
WO2016128970A1 (en) 2016-08-18
CA2975710A1 (en) 2016-08-18
JP2023100920A (ja) 2023-07-19
EP3256152A4 (en) 2018-11-14
WO2016128974A1 (en) 2016-08-18
IL283258B1 (en) 2023-07-01
IL253802B (en) 2022-06-01
IL283258A (en) 2021-07-29
WO2016128972A1 (en) 2016-08-18
IL253803A0 (en) 2017-09-28
IL253802A0 (en) 2017-09-28
CN113713090B (zh) 2023-06-02
JP7275207B2 (ja) 2023-05-17
EP3256114A4 (en) 2018-11-21
HK1247823A1 (zh) 2018-10-05
EP3256153A4 (en) 2018-11-21
EP3256153A1 (en) 2017-12-20
IL292218B2 (en) 2024-10-01
HK1247822A1 (zh) 2018-10-05
HK1247835A1 (zh) 2018-10-05
US20180036234A1 (en) 2018-02-08
BR112017017112A2 (pt) 2018-04-03
CA3011654A1 (en) 2016-08-18
JP6925970B2 (ja) 2021-08-25
EP3256113A4 (en) 2018-11-14
MX2022014313A (es) 2022-12-07
CN107427481A (zh) 2017-12-01
EP3256149A1 (en) 2017-12-20
US20180036382A1 (en) 2018-02-08
IL292417B1 (en) 2024-08-01
HK1247838A1 (zh) 2018-10-05
CA2975710C (en) 2023-08-08
US20240398904A1 (en) 2024-12-05
US20200138913A1 (en) 2020-05-07
WO2016128973A1 (en) 2016-08-18
JP2021176914A (ja) 2021-11-11
JP2018504444A (ja) 2018-02-15
CN113713090A (zh) 2021-11-30
US20180050096A1 (en) 2018-02-22
EP3256114A1 (en) 2017-12-20
EP3256113A1 (en) 2017-12-20
US20240181020A1 (en) 2024-06-06
IL292417A (en) 2022-06-01
EP3256149A4 (en) 2019-08-14
JP2018504445A (ja) 2018-02-15
CA3011657A1 (en) 2016-08-18
WO2016128971A1 (en) 2016-08-18
IL253804A0 (en) 2017-09-28
CA2975676A1 (en) 2016-08-18
US10583177B2 (en) 2020-03-10
US12076373B2 (en) 2024-09-03
JP2023055902A (ja) 2023-04-18
HK1247843A1 (zh) 2018-10-05
EP3256152A1 (en) 2017-12-20
IL253803B (en) 2021-06-30

Similar Documents

Publication Publication Date Title
JP7775239B2 (ja) 骨粗鬆症の治療
JP7736834B2 (ja) 活性薬剤の経口投与のための製剤
HK40064924B (en) Treatment of osteoporosis
HK40078392A (en) Treatment of osteoporosis
HK40064568A (en) Treatment of osteoporosis
HK40064572A (en) Treatment of osteoporosis
HK40064924A (en) Treatment of osteoporosis
HK40064568B (zh) 骨质疏松症的治疗
CA2975578C (en) Treatment of hypoparathyroidism
BR112017017112B1 (pt) Composição farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171019

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20171018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190131

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190131

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20190710

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190819

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210402

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210706

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210804

R150 Certificate of patent or registration of utility model

Ref document number: 6925969

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250